Pharmaceutical and biotech competitive intelligence is increasingly important and challenging these days. Lacerta Bio discusses a recent case study in which a client learned this the hard way.
Lacerta Bio is pleased to announce our attendance at the upcoming BIO-Europe 2012 conference in Hamburg, Germany. In our view, the Fall version of BIO-Europe is the premier partnering…
In response to the recent acquisition of Medicis by Valeant, an interesting poll underway asking a seemingly simple question, "Will other pharma companies follow Valeant and abandon R&D in favor…
At Lacerta Bio, we're in the middle of several international out-licensing projects. This process is enabling us to re-connect with many companies around the world. In addition, we're making new…
We generally agree with the notion that many early-stage biotechs should be structured as LLCs instead of C corps. This short interview with Attorney Albert L. Sokol highlights one key…
As we read the continuing bad news regarding venture financing in biotech, we came across this bit of news from the UK: BioCity Nottingham-based CompanDX Limited, the Nottingham Trent University…
On Friday, it was announced that the former Pfizer R&D center in Kent, UK, was sold: The new agreement with Discovery Park will see the consortium take over 297 acres…
We were disappointed to read this yesterday: Pfizer ($PFE) and Johnson & Johnson ($JNJ) have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase…
Thank goodness for Twitter. How else can one keep up with all of the news and happenings in our industry during the "slow" month of July? Here are a few…
A recent article in Forbes by ex-Pfizer President or R&D John LaMattina asks a provocative question: Will Pricing Be a Key Differentiator For New Drugs? I recall some 10-15 years…